CheqUp holds Mounjaro prices on 2.5mg and 5mg to protect patients after Eli Lilly hike

  • Prices for Mounjaro 2.5mg and 5mg held at £149 and £169 respectively from Monday, with CheqUp absorbing increased costs to protect patients
  • Company reported a 27-fold surge (2,660%) in UK sales of Wegovy following price rises to rival medication
  • Impact assessment report indicates up to 80% of Mounjaro patients will switch or come off treatment due to higher costs, with upwards of 625,000 people potentially moving to Wegovy

London, Monday 1st September: Weight loss medication provider, CheqUp, announced it will maintain the current prices of Mounjaro 2.5mg at £149 and 5mg at £169 from today, Monday 1 September, following recent price increases by Eli Lilly. The decision is designed to minimise disruption for patients starting treatment, prevent affordability shocks on the most commonly initiated doses, and reduce the risk of people turning to unregulated sources.

It comes after the company highlighted growing concerns that sudden price rises risk pushing people to black or grey markets, where unregulated products and irregular dosing can compromise safety.

The higher doses are increasing to factor in higher costs from Eli Lily – 7.5mg (£249), 10mg (£289),12.5mg (£299) and 15.0mg (£329) though CheqUp notes that its increases remain lower than many others in the industry.

CheqUp has consistently raised concerns that sudden cost rises risk pushing patients to black or grey markets, where unregulated products and irregular dosing can compromise safety. Following Eli Lilly’s changes, the company recorded a 27-fold surge (2,660%) in UK sales of Novo Nordisk’s Wegovy, a cheaper alternative. CheqUp’s impact assessment, based on a survey of UK weight loss patients, indicates that as many as 80% of Mounjaro patients may switch or stop treatment altogether due to affordability pressures.

With an estimated 1.25 million people in the UK currently taking weight loss medication, and over 90% believed to be prescribed Mounjaro, the data suggests that upwards of 625,000 people may switch or be in the process of switching to Wegovy.

Eli Lilly has increased Mounjaro pricing to align with other European markets, primarily due to political pressures in the United States. CheqUp warns that the move affects more than a million people in the UK currently using weight loss medication, with significant implications for continuity of care and patient safety.

Toby Nicol, CEO at CheqUp, said: “We are maintaining the price of Mounjaro 2.5mg and 5mg, to protect patients from being priced out of essential treatment. Abrupt affordability shocks risk pushing people towards unsafe, unregulated alternatives. While we’ve needed to adapt prices on higher doses to reflect supplier costs, it was important to us to shield patients at the most common starting doses.

“Go on any social media site and you can find cowboy operators – drug dealers, for all intents and purposes – exploiting confused patients who can no longer afford treatment but want to continue. As with most things in life, if it looks too good to be true, it probably is.

“Our priority is continuity of care and patient safety. We’re absorbing additional costs on the lower doses for as long as possible, but if supplier costs rise further, prices may need to be reviewed. Should that happen, we will do everything possible to manage changes responsibly and with clear communication to patients.”

How users can safely make the switch 

Current Mounjaro patients worried by the affordability of new prices are able to switch to Wegovy with CheqUp, with the dose they can switch to depending on the Mounjaro dose they are on – providing it is clinically safe to do so.

CheqUp’s clinical team has outlined what this plan looks like for users across different Mounjaro doses. This has been decided on a clinical basis, and notably it reflects the principle that those patients moving from Mounjaro to Wegovy are moving from a medication consisting of two molecules (GLP-1 and GIP) to one with only a single molecule (GLP-1).

Image Credit: Lisa Baker